Cycling the Tour de France on One Lung: Chris Froome

What Chris Froome dealt with

Bilharzia, also called schistosomiasis, is a parasitic infection caused by Schistosoma worms. The parasite is endemic in parts of sub Saharan Africa including Kenya where Froome grew up. He was diagnosed with the infection during his early professional career and managed the condition throughout his most successful years.

The cyclist

Chris Froome was born in Nairobi, Kenya in 1985 and grew up in Africa before moving to Europe to pursue professional cycling. He turned professional in 2007 and rode for Team Sky from 2010 onward. He won the Tour de France four times, the Giro d Italia once and the Vuelta a Espana twice across his career. He is one of only a small number of cyclists to win all three grand tours.

The diagnosis

Froome was diagnosed with bilharzia in 2010 after years of unexplained underperformance and chronic fatigue. The infection had been present for some time before diagnosis. Once identified he was treated with praziquantel, the standard antiparasitic medication. Treatment cleared the active infection but some chronic effects on his pulmonary system persisted.

The clinical picture

Bilharzia can cause chronic inflammatory damage to multiple organ systems. In Froomes case the pulmonary effects appeared to be the most significant. Reports suggested reduced lung capacity and impaired oxygen transfer at altitude. The phrase racing on one lung was used informally in cycling media to describe the perceived deficit, although it overstated the literal medical reality.

The performance

Despite the chronic effects Froome went on to win 7 grand tours including 4 Tours de France. His sustained climbing performance and time trial output were among the best of his generation. The case is not one of clean physiological excellence but of adaptation around chronic limitation.

How bilharzia affects endurance capacity

Schistosomiasis is a complex chronic infection that can affect multiple organ systems including the liver, urinary tract and lungs. The pulmonary form is less common but can produce lasting effects on oxygen transport.

The parasite

Schistosoma worms enter the body through the skin during freshwater contact, typically in lakes and rivers in endemic areas. The worms migrate through the bloodstream and lodge in various organs depending on species. They release eggs that produce ongoing inflammatory damage. The infection can persist for decades if untreated.

Pulmonary involvement

The pulmonary form of schistosomiasis affects the small blood vessels of the lung. Inflammatory damage can produce pulmonary hypertension and reduced gas exchange efficiency. Chronic cases may show reduced diffusing capacity. In Froomes case the reported reduction in effective lung function appeared to be modest but measurable.

Cardiovascular compensation

When pulmonary function is impaired the cardiovascular system can partly compensate through increased cardiac output, plasma volume expansion and red blood cell production. Endurance training amplifies these adaptations. An athlete with mildly reduced pulmonary function may still deliver adequate oxygen to working muscles through enhanced cardiovascular delivery.

Treatment effects

Praziquantel kills adult worms and stops new egg production. Treatment can produce inflammatory responses as the dying parasites are cleared. Lasting tissue damage from the years of infection may not fully reverse. Froome continued to manage chronic effects after treatment cleared the active infection.

What elite grand tour cycling demands

The Tour de France is a 21 day stage race covering approximately 3500 km with multiple high mountain stages. Winning requires sustained high power output at altitude across three weeks of consecutive racing.

Total demand

A grand tour rider expends approximately 7000 to 9000 kcal per day across the race. Total caloric demand over 21 days approaches 200,000 kcal. Time on the bike is 90 to 120 hours total. The cumulative cardiovascular and metabolic load is among the highest in any sport.

Mountain stage demand

The decisive stages are mountain stages with sustained climbs at 8 to 12 percent gradient lasting 45 minutes or longer. Peak power output on these climbs sits at 6.0 to 6.5 W/kg for elite riders. The output is sustained at or near lactate threshold for sustained periods. This is where pulmonary efficiency matters most.

Time trial demand

Time trial stages are individual efforts against the clock typically 30 to 50 km. Output is sustained at threshold or slightly above. Pulmonary capacity and cardiac efficiency are both critical. Froome was an effective time trialist as well as climber, suggesting his pulmonary limitation did not prevent high sustained output.

Recovery demand

Grand tour racing requires extreme recovery capacity between consecutive stages. Athletes eat substantial volumes of food, sleep 9 to 10 hours per night and have full team support for massage, nutrition and equipment. Recovery efficiency may be as important as raw power output for grand tour success.

Lessons from the Froome story

The Froome case illustrates how elite endurance performance is possible despite chronic medical conditions when supported by appropriate treatment, adaptation and training. The lessons apply across endurance sport.

Diagnosis matters

Years of unexplained underperformance can have specific medical causes. Froome was performing below his potential before bilharzia was diagnosed. Identifying and treating the underlying condition unlocked the performance ceiling. For athletes with persistent fatigue or underperformance, thorough medical investigation can reveal addressable causes.

The body adapts

When one physiological system is impaired, others can partly compensate. Cardiovascular and metabolic adaptations can offset moderate pulmonary limitations. The body has significant adaptive capacity that becomes visible only when one component is impaired and others are pushed to compensate.

Chronic conditions are not always disqualifying

Elite sport often involves athletes managing chronic conditions. Asthma, type 1 diabetes, autoimmune conditions and various other diagnoses are present at the highest level of competition. Appropriate medical management combined with training can allow performance well above what the diagnosis alone would predict.

The clean cyclist debate

Froomes performance and subsequent positive test for salbutamol in 2017 raised questions about how clean grand tour cycling actually is. The salbutamol case was eventually resolved in his favour but it sits in the broader context of cycling history. The Froome story should be read with awareness that cycling has had documented doping issues. The medical case for his pulmonary limitation is real. Other aspects remain contested.

More from the limits library

For another endurance limit case, our Breaking the Ironman Barrier guide covers Jan Frodeno. Sub Two Hour Marathon covers Eliud Kipchoge. And Running on Minimal Body Fat covers Haile Gebrselassie and another endurance physiology case.